Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-07-08

AUTHORS

R Sakai, K Ohmachi, F Sano, R Watanabe, H Takahashi, H Takasaki, M Tanaka, Y Hattori, H Kimura, M Takimoto, T Tachibana, E Tanaka, Y Ishii, Y Ishiyama, M Hagihara, K Miyazaki, K Yamamoto, N Tomita, K Ando

ABSTRACT

The optimal dose, schedule, and other aspects of bendamustine plus rituximab treatment remain unclear for patients with relapsed or refractory follicular lymphoma (FL). Herein, we analyzed the efficacy of bendamustine combined with rituximab (RB-120) treatment for Japanese patients with relapsed or refractory FL. This phase II clinical trial included patients with relapsed or refractory FL who received 375 mg/m2 rituximab on day 1 and 120 mg/m2 bendamustine on days 2 and 3 every 28 days for up to 6 cycles. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and safety. Thirty-seven patients were enrolled in the trial (median age 62 years, range 42–75 years). All patients were previously treated with rituximab-containing chemotherapy, and 83.8% were previously treated with the R-CHOP regimen. A median of 5 cycles (range 1–6) and 48.6% of patients completed 6 cycles. The ORR was 91.9% (95% confidence interval [CI] 78.1–98.3%), with a CR rate of 86.5% (95% CI 71.2–95.5%). The 3-year PFS and OS were 70.9% (95% CI 52.3–83.3%) and 88.9% (95% CI 73.1–95.7%), respectively, with the median 39.5 months follow-up duration. The most-frequently observed grade 3/4 adverse events were hematologic: lymphopenia (95%) and neutropenia (70%). No treatment-related deaths were observed. RB-120 showed a good efficacy with equivalent toxicities, compared with the bendamustine 120 mg/m2 monotherapy. However, the problem of high drop-out incidences cannot be ignored. More... »

PAGES

2131-2138

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-019-03750-7

DOI

http://dx.doi.org/10.1007/s00277-019-03750-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1117831570

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31286196


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bendamustine Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Follicular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakai", 
        "givenName": "R", 
        "id": "sg:person.01300452360.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265061.6", 
          "name": [
            "Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohmachi", 
        "givenName": "K", 
        "id": "sg:person.01321520521.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321520521.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417363.4", 
          "name": [
            "Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sano", 
        "givenName": "F", 
        "id": "sg:person.01314144575.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314144575.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "R", 
        "id": "sg:person.012637131732.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012637131732.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan", 
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "H", 
        "id": "sg:person.0711631331.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711631331.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takasaki", 
        "givenName": "H", 
        "id": "sg:person.0774122402.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "M", 
        "id": "sg:person.01171141246.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Y", 
        "id": "sg:person.01015062766.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015062766.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "H", 
        "id": "sg:person.016265736132.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016265736132.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417363.4", 
          "name": [
            "Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takimoto", 
        "givenName": "M", 
        "id": "sg:person.015432173733.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015432173733.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tachibana", 
        "givenName": "T", 
        "id": "sg:person.01074653417.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Shounan Kamakura General Hospital, Kamakura, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Hematology, Shounan Kamakura General Hospital, Kamakura, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "E", 
        "id": "sg:person.015432307121.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015432307121.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishii", 
        "givenName": "Y", 
        "id": "sg:person.0665120613.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishiyama", 
        "givenName": "Y", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hagihara", 
        "givenName": "M", 
        "id": "sg:person.0663130331.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyazaki", 
        "givenName": "K", 
        "id": "sg:person.013672700062.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013672700062.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "K", 
        "id": "sg:person.013260042324.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013260042324.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "N", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265061.6", 
          "name": [
            "Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ando", 
        "givenName": "K", 
        "id": "sg:person.015274442102.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015274442102.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12185-016-2146-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053131460", 
          "https://doi.org/10.1007/s12185-016-2146-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-07-08", 
    "datePublishedReg": "2019-07-08", 
    "description": "The optimal dose, schedule, and other aspects of bendamustine plus rituximab treatment remain unclear for patients with relapsed or refractory follicular lymphoma (FL). Herein, we analyzed the efficacy of bendamustine combined with rituximab (RB-120) treatment for Japanese patients with relapsed or refractory FL. This phase II clinical trial included patients with relapsed or refractory FL who received 375\u00a0mg/m2 rituximab on day 1 and 120\u00a0mg/m2 bendamustine on days 2 and 3 every 28\u00a0days for up to 6\u00a0cycles. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and safety. Thirty-seven patients were enrolled in the trial (median age 62\u00a0years, range 42\u201375\u00a0years). All patients were previously treated with rituximab-containing chemotherapy, and 83.8% were previously treated with the R-CHOP regimen. A median of 5\u00a0cycles (range 1\u20136) and 48.6% of patients completed 6\u00a0cycles. The ORR was 91.9% (95% confidence interval [CI] 78.1\u201398.3%), with a CR rate of 86.5% (95% CI 71.2\u201395.5%). The 3-year PFS and OS were 70.9% (95% CI 52.3\u201383.3%) and 88.9% (95% CI 73.1\u201395.7%), respectively, with the median 39.5\u00a0months follow-up duration. The most-frequently observed grade 3/4 adverse events were hematologic: lymphopenia (95%) and neutropenia (70%). No treatment-related deaths were observed. RB-120 showed a good efficacy with equivalent toxicities, compared with the bendamustine 120\u00a0mg/m2 monotherapy. However, the problem of high drop-out incidences cannot be ignored.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-019-03750-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "98"
      }
    ], 
    "keywords": [
      "refractory follicular lymphoma", 
      "progression-free survival", 
      "overall response rate", 
      "follicular lymphoma", 
      "overall survival", 
      "rituximab treatment", 
      "observed grade 3/4 adverse events", 
      "response rate", 
      "grade 3/4 adverse events", 
      "multicenter phase II study", 
      "phase II clinical trial", 
      "efficacy of bendamustine", 
      "complete response rate", 
      "rituximab-containing chemotherapy", 
      "treatment-related deaths", 
      "phase II study", 
      "R-CHOP regimen", 
      "primary endpoint", 
      "secondary endpoints", 
      "rituximab therapy", 
      "II study", 
      "adverse events", 
      "CR rate", 
      "Japanese patients", 
      "clinical trials", 
      "optimal dose", 
      "patients", 
      "day 1", 
      "day 2", 
      "better efficacy", 
      "bendamustine", 
      "RB 120", 
      "lymphoma", 
      "trials", 
      "endpoint", 
      "efficacy", 
      "survival", 
      "treatment", 
      "high drop", 
      "equivalent toxicity", 
      "rituximab", 
      "neutropenia", 
      "monotherapy", 
      "lymphopenia", 
      "regimen", 
      "chemotherapy", 
      "therapy", 
      "incidence", 
      "dose", 
      "months", 
      "median", 
      "death", 
      "rate", 
      "toxicity", 
      "duration", 
      "days", 
      "safety", 
      "schedule", 
      "study", 
      "events", 
      "cycle", 
      "Herein", 
      "aspects", 
      "drop", 
      "problem"
    ], 
    "name": "Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study", 
    "pagination": "2131-2138", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1117831570"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-019-03750-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31286196"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-019-03750-7", 
      "https://app.dimensions.ai/details/publication/pub.1117831570"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_826.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-019-03750-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-019-03750-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-019-03750-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-019-03750-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-019-03750-7'


 

This table displays all metadata directly associated to this object as RDF triples.

339 TRIPLES      22 PREDICATES      107 URIs      97 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-019-03750-7 schema:about N06eb59a485074e1180e50b6120b5d55f
2 N2730ec498e1247fcadea2a4622f781c2
3 N339de2fb69164e62a18d91d07ddc53d1
4 N3ac9cc7218a548769f22f4f8bfb29dc7
5 N3d6b8997716848a0bb1bc6ee0011f302
6 N509d5e6c44ba48b99aecb5050bed7ee9
7 N9829197d663e4ab9851952ffbd71e488
8 N9d7a4e4d290a494295a47e97933078b8
9 Na7ab1a90681a41ca8f5608b41b93c95d
10 Nad511cd2e3e94ef9befc7e59ee799503
11 Nb271ddfe958d4b0cb79c67734ecb571b
12 Nc1cb058ab47e4331bbe6ef153a36c946
13 Nc701f40f8ca7486796cf2a10219f3da7
14 Nf854c5da44ee4ec791911893493fc0c9
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Nb26de914a11647cb9749b9b0487b8a13
18 schema:citation sg:pub.10.1007/s12185-016-2146-4
19 sg:pub.10.1038/bmt.2012.244
20 schema:datePublished 2019-07-08
21 schema:datePublishedReg 2019-07-08
22 schema:description The optimal dose, schedule, and other aspects of bendamustine plus rituximab treatment remain unclear for patients with relapsed or refractory follicular lymphoma (FL). Herein, we analyzed the efficacy of bendamustine combined with rituximab (RB-120) treatment for Japanese patients with relapsed or refractory FL. This phase II clinical trial included patients with relapsed or refractory FL who received 375 mg/m2 rituximab on day 1 and 120 mg/m2 bendamustine on days 2 and 3 every 28 days for up to 6 cycles. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and safety. Thirty-seven patients were enrolled in the trial (median age 62 years, range 42–75 years). All patients were previously treated with rituximab-containing chemotherapy, and 83.8% were previously treated with the R-CHOP regimen. A median of 5 cycles (range 1–6) and 48.6% of patients completed 6 cycles. The ORR was 91.9% (95% confidence interval [CI] 78.1–98.3%), with a CR rate of 86.5% (95% CI 71.2–95.5%). The 3-year PFS and OS were 70.9% (95% CI 52.3–83.3%) and 88.9% (95% CI 73.1–95.7%), respectively, with the median 39.5 months follow-up duration. The most-frequently observed grade 3/4 adverse events were hematologic: lymphopenia (95%) and neutropenia (70%). No treatment-related deaths were observed. RB-120 showed a good efficacy with equivalent toxicities, compared with the bendamustine 120 mg/m2 monotherapy. However, the problem of high drop-out incidences cannot be ignored.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N8e547ea8a91b4415abeca0e5b7e8f200
27 Ndaccbec493b04b8c8168633d13710080
28 sg:journal.1358129
29 schema:keywords CR rate
30 Herein
31 II study
32 Japanese patients
33 R-CHOP regimen
34 RB 120
35 adverse events
36 aspects
37 bendamustine
38 better efficacy
39 chemotherapy
40 clinical trials
41 complete response rate
42 cycle
43 day 1
44 day 2
45 days
46 death
47 dose
48 drop
49 duration
50 efficacy
51 efficacy of bendamustine
52 endpoint
53 equivalent toxicity
54 events
55 follicular lymphoma
56 grade 3/4 adverse events
57 high drop
58 incidence
59 lymphoma
60 lymphopenia
61 median
62 monotherapy
63 months
64 multicenter phase II study
65 neutropenia
66 observed grade 3/4 adverse events
67 optimal dose
68 overall response rate
69 overall survival
70 patients
71 phase II clinical trial
72 phase II study
73 primary endpoint
74 problem
75 progression-free survival
76 rate
77 refractory follicular lymphoma
78 regimen
79 response rate
80 rituximab
81 rituximab therapy
82 rituximab treatment
83 rituximab-containing chemotherapy
84 safety
85 schedule
86 secondary endpoints
87 study
88 survival
89 therapy
90 toxicity
91 treatment
92 treatment-related deaths
93 trials
94 schema:name Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
95 schema:pagination 2131-2138
96 schema:productId N31e0b715570d4dec9ef9eca872bf1cd8
97 Nb90e65d5574e4dc385a5c1153fe4f6c8
98 Nf9bf025e0ff54189af71bf21069ae94f
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117831570
100 https://doi.org/10.1007/s00277-019-03750-7
101 schema:sdDatePublished 2022-05-20T07:36
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Na907e91c07464e6b9d3d29feae861f37
104 schema:url https://doi.org/10.1007/s00277-019-03750-7
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N06eb59a485074e1180e50b6120b5d55f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Rituximab
110 rdf:type schema:DefinedTerm
111 N1095601b852e419f86a2170fe92f2f1d rdf:first sg:person.012637131732.19
112 rdf:rest N8eede4ad2ed44613bacc9963baa98e2c
113 N16624be3f5d8479e98fa476452e7da15 rdf:first sg:person.015274442102.98
114 rdf:rest rdf:nil
115 N2730ec498e1247fcadea2a4622f781c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Aged
117 rdf:type schema:DefinedTerm
118 N30044627fe8d4bf79c49fffb56200be9 rdf:first sg:person.01171141246.33
119 rdf:rest N3805840a225347e6af364ad2865caffb
120 N31e0b715570d4dec9ef9eca872bf1cd8 schema:name doi
121 schema:value 10.1007/s00277-019-03750-7
122 rdf:type schema:PropertyValue
123 N338b0239e3be4e7cb1584c82a824f031 rdf:first sg:person.01321520521.34
124 rdf:rest Ncf45985dadc74616a642249a00b3ec4a
125 N339de2fb69164e62a18d91d07ddc53d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Bendamustine Hydrochloride
127 rdf:type schema:DefinedTerm
128 N3805840a225347e6af364ad2865caffb rdf:first sg:person.01015062766.23
129 rdf:rest N646bf8945da34267ae88fdaf82194a70
130 N3ac9cc7218a548769f22f4f8bfb29dc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Neutropenia
132 rdf:type schema:DefinedTerm
133 N3d6b8997716848a0bb1bc6ee0011f302 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Disease-Free Survival
135 rdf:type schema:DefinedTerm
136 N509d5e6c44ba48b99aecb5050bed7ee9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Male
138 rdf:type schema:DefinedTerm
139 N56e62e9ee45a4f03b8f95a1a6b46d2bd rdf:first Nc200b3a1971a45d5b5525395d681a828
140 rdf:rest Ndaf728740f63461ba48891091a84fc88
141 N581584f84c164261932a98de359fd4d2 rdf:first sg:person.01155656464.01
142 rdf:rest N16624be3f5d8479e98fa476452e7da15
143 N646bf8945da34267ae88fdaf82194a70 rdf:first sg:person.016265736132.51
144 rdf:rest N9d1869855969486cbcbb23780e99f088
145 N73d0503e512b43a2a0c201b0bffabb8a rdf:first sg:person.01074653417.74
146 rdf:rest Na6b585ccf0834eeda9b7cab2a9ee98be
147 N7edc8a1bd05843ee8aa3d84753ae0c6f rdf:first sg:person.0774122402.27
148 rdf:rest N30044627fe8d4bf79c49fffb56200be9
149 N8160bea0e0f74f52b351cf2bb6d21336 rdf:first sg:person.0665120613.58
150 rdf:rest N56e62e9ee45a4f03b8f95a1a6b46d2bd
151 N8e547ea8a91b4415abeca0e5b7e8f200 schema:issueNumber 9
152 rdf:type schema:PublicationIssue
153 N8eede4ad2ed44613bacc9963baa98e2c rdf:first sg:person.0711631331.23
154 rdf:rest N7edc8a1bd05843ee8aa3d84753ae0c6f
155 N9829197d663e4ab9851952ffbd71e488 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 N9d1869855969486cbcbb23780e99f088 rdf:first sg:person.015432173733.59
159 rdf:rest N73d0503e512b43a2a0c201b0bffabb8a
160 N9d7a4e4d290a494295a47e97933078b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Lymphoma, Follicular
162 rdf:type schema:DefinedTerm
163 Na6b585ccf0834eeda9b7cab2a9ee98be rdf:first sg:person.015432307121.34
164 rdf:rest N8160bea0e0f74f52b351cf2bb6d21336
165 Na7ab1a90681a41ca8f5608b41b93c95d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Antineoplastic Combined Chemotherapy Protocols
167 rdf:type schema:DefinedTerm
168 Na907e91c07464e6b9d3d29feae861f37 schema:name Springer Nature - SN SciGraph project
169 rdf:type schema:Organization
170 Nad511cd2e3e94ef9befc7e59ee799503 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Survival Rate
172 rdf:type schema:DefinedTerm
173 Nb26de914a11647cb9749b9b0487b8a13 rdf:first sg:person.01300452360.13
174 rdf:rest N338b0239e3be4e7cb1584c82a824f031
175 Nb271ddfe958d4b0cb79c67734ecb571b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Middle Aged
177 rdf:type schema:DefinedTerm
178 Nb90e65d5574e4dc385a5c1153fe4f6c8 schema:name dimensions_id
179 schema:value pub.1117831570
180 rdf:type schema:PropertyValue
181 Nc1cb058ab47e4331bbe6ef153a36c946 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 Nc200b3a1971a45d5b5525395d681a828 schema:affiliation grid-institutes:grid.268441.d
185 schema:familyName Ishiyama
186 schema:givenName Y
187 rdf:type schema:Person
188 Nc701f40f8ca7486796cf2a10219f3da7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Follow-Up Studies
190 rdf:type schema:DefinedTerm
191 Ncc4757ed165b4ffb8073b1f29b6f2b78 rdf:first sg:person.013260042324.47
192 rdf:rest N581584f84c164261932a98de359fd4d2
193 Ncf45985dadc74616a642249a00b3ec4a rdf:first sg:person.01314144575.00
194 rdf:rest N1095601b852e419f86a2170fe92f2f1d
195 Nd823c6c6ffc64789a3339acd97046a6f rdf:first sg:person.013672700062.32
196 rdf:rest Ncc4757ed165b4ffb8073b1f29b6f2b78
197 Ndaccbec493b04b8c8168633d13710080 schema:volumeNumber 98
198 rdf:type schema:PublicationVolume
199 Ndaf728740f63461ba48891091a84fc88 rdf:first sg:person.0663130331.38
200 rdf:rest Nd823c6c6ffc64789a3339acd97046a6f
201 Nf854c5da44ee4ec791911893493fc0c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Adult
203 rdf:type schema:DefinedTerm
204 Nf9bf025e0ff54189af71bf21069ae94f schema:name pubmed_id
205 schema:value 31286196
206 rdf:type schema:PropertyValue
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:journal.1358129 schema:issn 0939-5555
214 1432-0584
215 schema:name Annals of Hematology
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.01015062766.23 schema:affiliation grid-institutes:grid.268441.d
219 schema:familyName Hattori
220 schema:givenName Y
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015062766.23
222 rdf:type schema:Person
223 sg:person.01074653417.74 schema:affiliation grid-institutes:grid.413045.7
224 schema:familyName Tachibana
225 schema:givenName T
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74
227 rdf:type schema:Person
228 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.268441.d
229 schema:familyName Tomita
230 schema:givenName N
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
232 rdf:type schema:Person
233 sg:person.01171141246.33 schema:affiliation grid-institutes:grid.413045.7
234 schema:familyName Tanaka
235 schema:givenName M
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33
237 rdf:type schema:Person
238 sg:person.012637131732.19 schema:affiliation grid-institutes:grid.414944.8
239 schema:familyName Watanabe
240 schema:givenName R
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012637131732.19
242 rdf:type schema:Person
243 sg:person.01300452360.13 schema:affiliation grid-institutes:grid.414944.8
244 schema:familyName Sakai
245 schema:givenName R
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13
247 rdf:type schema:Person
248 sg:person.01314144575.00 schema:affiliation grid-institutes:grid.417363.4
249 schema:familyName Sano
250 schema:givenName F
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314144575.00
252 rdf:type schema:Person
253 sg:person.01321520521.34 schema:affiliation grid-institutes:grid.265061.6
254 schema:familyName Ohmachi
255 schema:givenName K
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321520521.34
257 rdf:type schema:Person
258 sg:person.013260042324.47 schema:affiliation grid-institutes:None
259 schema:familyName Yamamoto
260 schema:givenName K
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013260042324.47
262 rdf:type schema:Person
263 sg:person.013672700062.32 schema:affiliation grid-institutes:grid.410786.c
264 schema:familyName Miyazaki
265 schema:givenName K
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013672700062.32
267 rdf:type schema:Person
268 sg:person.015274442102.98 schema:affiliation grid-institutes:grid.265061.6
269 schema:familyName Ando
270 schema:givenName K
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015274442102.98
272 rdf:type schema:Person
273 sg:person.015432173733.59 schema:affiliation grid-institutes:grid.417363.4
274 schema:familyName Takimoto
275 schema:givenName M
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015432173733.59
277 rdf:type schema:Person
278 sg:person.015432307121.34 schema:affiliation grid-institutes:None
279 schema:familyName Tanaka
280 schema:givenName E
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015432307121.34
282 rdf:type schema:Person
283 sg:person.016265736132.51 schema:affiliation grid-institutes:grid.410786.c
284 schema:familyName Kimura
285 schema:givenName H
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016265736132.51
287 rdf:type schema:Person
288 sg:person.0663130331.38 schema:affiliation grid-institutes:grid.268441.d
289 schema:familyName Hagihara
290 schema:givenName M
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38
292 rdf:type schema:Person
293 sg:person.0665120613.58 schema:affiliation grid-institutes:grid.268441.d
294 schema:familyName Ishii
295 schema:givenName Y
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58
297 rdf:type schema:Person
298 sg:person.0711631331.23 schema:affiliation grid-institutes:grid.268441.d
299 schema:familyName Takahashi
300 schema:givenName H
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711631331.23
302 rdf:type schema:Person
303 sg:person.0774122402.27 schema:affiliation grid-institutes:grid.414944.8
304 schema:familyName Takasaki
305 schema:givenName H
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27
307 rdf:type schema:Person
308 sg:pub.10.1007/s12185-016-2146-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053131460
309 https://doi.org/10.1007/s12185-016-2146-4
310 rdf:type schema:CreativeWork
311 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
312 https://doi.org/10.1038/bmt.2012.244
313 rdf:type schema:CreativeWork
314 grid-institutes:None schema:alternateName Department of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan
315 Division of Hematology, Shounan Kamakura General Hospital, Kamakura, Japan
316 schema:name Department of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan
317 Division of Hematology, Shounan Kamakura General Hospital, Kamakura, Japan
318 rdf:type schema:Organization
319 grid-institutes:grid.265061.6 schema:alternateName Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
320 schema:name Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
321 rdf:type schema:Organization
322 grid-institutes:grid.268441.d schema:alternateName Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
323 schema:name Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
324 Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan
325 rdf:type schema:Organization
326 grid-institutes:grid.410786.c schema:alternateName Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan
327 Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Japan
328 schema:name Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan
329 Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Japan
330 rdf:type schema:Organization
331 grid-institutes:grid.413045.7 schema:alternateName Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
332 schema:name Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
333 rdf:type schema:Organization
334 grid-institutes:grid.414944.8 schema:alternateName Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan
335 schema:name Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-0815, Yokohama, Japan
336 rdf:type schema:Organization
337 grid-institutes:grid.417363.4 schema:alternateName Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan
338 schema:name Department of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan
339 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...